ArticleBone2012
Follicle-stimulating hormone is independently associated with lean mass but not BMD in younger postmenopausal women.
Article in Bone, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 40 citations in OpenAlex.
- FSH suppression does not affect bone turnover in eugonadal men.The Journal of clinical endocrinology and metabolism · 2014Trial
- Associations between hormones, metabolic markers, and bone mass in perimenopausal and postmenopausal women.Journal of bone and mineral metabolism · 2025Article
- VARIANCE AS A PREDICTOR OF HEALTH OUTCOMES: SUBJECT-LEVEL TRAJECTORIES AND VARIABILITY OF SEX HORMONES TO PREDICT BODY FAT CHANGES IN PERI- AND POSTMENOPAUSAL WOMEN.The annals of applied statistics · 2024Article
- Article
- Follicle-stimulating hormone is associated with low bone mass in postmenopausal women.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2023Article
- Associations of Serum Follicle-Stimulating Hormone and Luteinizing Hormone Levels with Fat and Lean Mass during Menopausal Transition.Obesity facts · 2023Article
- Roles of Follicle-Stimulating Hormone on Bone Metabolism in Late Postmenopausal Women.Journal of bone metabolism · 2022Article
- Effects of follicle-stimulating hormone on fat metabolism and cognitive impairment in women during menopause.Frontiers in physiology · 2022Review
- Serum FSH Is Associated With BMD, Bone Marrow Adiposity, and Body Composition in the AGES-Reykjavik Study of Older Adults.The Journal of clinical endocrinology and metabolism · 2021Observational
- Association Between Serum Follicle-Stimulating Hormone and Sarcopenia and Physical Disability Among Older Chinese Men: Evidence From a Cross-Sectional Study.Frontiers in medicine · 2021Article
- Relationships between Follicle-Stimulating Hormone and Adiponectin in Postmenopausal Women.Metabolites · 2020Article
- FSH-metabolic circuitry and menopause.Journal of molecular endocrinology · 2019Review
- FSH Beyond Fertility.Frontiers in endocrinology · 2019Review
- Review
- FSH, Bone Mass, Body Fat, and Biological Aging.Endocrinology · 2018Article
- Actions of pituitary hormones beyond traditional targets.The Journal of endocrinology · 2018Review
- The Relationship between Follicle-stimulating Hormone and Bone Health: Alternative Explanation for Bone Loss beyond Oestrogen?International journal of medical sciences · 2018Review
- Review
- Bone Mineral Density in Adolescent Girls with Hypogonadotropic and Hypergonadotropic Hypogonadism.Journal of clinical research in pediatric endocrinology · 2016Article
- Follicle-Stimulating Hormone Increases the Risk of Postmenopausal Osteoporosis by Stimulating Osteoclast Differentiation.PloS one · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
purposeIncreased follicle-stimulating hormone (FSH) has been associated with lower bone mineral density (BMD) in animal models and longitudinal studies of women, but a direct effect has not been demonstrated.
methodsWe tested associations between FSH, non-bone body composition measures and BMD in 94 younger (aged 50 to 64 years) postmenopausal women without current use of hormone therapy, adjusting for sex hormone concentrations and clinical risk factors for osteoporosis. Lean mass, fat mass and areal BMD (aBMD) at the spine, femoral neck and total hip were measured using dual energy X-ray absorptiometry (DXA). Volumetric BMD (vBMD) was measured at the distal radius using peripheral quantitative computed tomography (pQCT).
resultsFSH was inversely correlated with lean and fat mass, bioavailable estradiol, spine and hip aBMD, and vBMD at the ultradistal radius. In the multivariable analysis, FSH was independently associated with lean mass (β=-0.099, p=0.005) after adjustment for age, race, years since menopause, bioavailable estradiol, bioavailable testosterone, LH, PTH, SHBG and urine N-telopeptide. FSH showed no statistically significant association with aBMD at any site or pQCT measures at the distal radius in adjusted models. Race was independently associated with aBMD, and race and urine N-telopeptide were independently associated with bone area and vBMD.
conclusionsAfter adjustment for hormonal measures and osteoporosis risk factors, higher concentrations of FSH were independently associated with lower lean mass, but not with BMD. Previously reported correlations between FSH and BMD might have been due to indirect associations via lean mass or weight.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.